Skip to content

Grail, Inc.

GRAL· NasdaqCore metricsCIK 1699031

Medical laboratories28 peers

Last sale
Nov 12, 2026 · -3.44%
Market cap
$5.45B
44.96M shares
Filings
269
$37.54M
Q3 2026+17.2% FY25 yoy
-$103.57M
Q3 2026N/M FY25 yoy
-$144.62M
Q3 2026N/M FY25 yoy
-$248.13M
Q3 2026derivedN/M FY25 yoy
-$2.21
Q3 2026N/M FY25 yoy
$28.98M
Q3 2026+16.6% FY25 yoy
$5.45B
—
32.7×
2.2×
-5.72%
—

Twelve months to Sep 30, 2026 · derived

Price

$121.25+45.40%+$37.86past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$147.17MFY 2025
$147.17M0FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$147,172,000reported
FY 20242024-12-31$125,595,000reported
FY 20232023-12-31$93,105,000reported
FY 20222023-01-01$55,550,000reported

Segments

Products
Revenue by Products, FY2023 to FY2025FY2023Screening revenue · FY2023 · $75.00MDevelopment Services · FY2023 · $18.11MFY2024Screening revenue · FY2024 · $108.63MDevelopment Services · FY2024 · $16.97MFY2025Screening revenue · FY2025 · $138.60MDevelopment Services · FY2025 · $8.57M
LineFY2025ShareChange
Screening revenue$138.60M94%+27.6%
Development Services$8.57M5.8%−49.5%
Total$147.17M

From the 10-K filed Mar 12, 2026GRAL

Medical laboratories

Grail, Inc. is the 13th largest of the 29 covered companies the SEC files under this code, by revenue. SIC 8071

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Grail, Inc. · CIK 1699031 · Engraved from SEC EDGAR